Joshua Zeidner, MD, has served as an Associate Professor of Medicine at the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, NC, since 2014. Dr Zeidner received his BA from Boston University in Boston, MA, in 2004, after which he received his medical degree from the New York Medical College in Valhalla, NY, in 2008. He completed a residency and fellowship at Johns Hopkins University in Baltimore, MA, in 2011 and 2014 respectively.
Dr Zeidner is the lead on the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group and the Principal Investigator on several clinical trials.
Speaking on patient-centered therapies for AML and MDS
Dr Zeidner specializes in the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms. In particular, his research focuses on developing new drugs and patient-centered therapeutic approaches to improve outcomes in AML and MDS.